A phase I/II study of docetaxel and gemcitabine combination for chemotherapy-resistant ovarian cancer
Yoshio Itani1, Kenichi Hosokawa, Kimihiko Ito
1Nara Prefectural Nara Hospital Ob & Gyn. 1-30-1 Hiramatsucho, Narashi Nara 631-0846, Japan. nuages@m3.kcn.ne.jp
Background:
A phase I/II study of docetaxel (DOC) and gemcitabine (GEM) combination for treatment-resistant ovarian cancer (OC) was conducted.
Materials And Methods:
Eligible patients exhibited recurrent OC within 12 months after initial treatment, or after more than 2 chemotherapy regimens. Planned dose levels (DL) were as follows: DOC 70 mg/m(2), GEM 800 mg/m(2) (DL1); DOC 70 mg/m(2), GEM 1000 mg/m(2) (DL2). DOC was administered on day 1 combined with GEM on days 1 and 8 every 3 weeks. Adverse events were assessed by NCI-CTC2.0J. Response was evaluated by RECIST or Rustin's criteria.
Results:
The recommended dose was DL1. For all enrolled patients, the median interval from last chemotherapy was 2.5 (1-11) months and 32 patients were assessable for response. One complete response, 6 partial responses and 6 stable disease were noted. Median time to progression was 4.8 months. Toxicities were mainly hematological and manageable.
Conclusion:
This combination could be an acceptable treatment option before palliation.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

